Search
Amiloxate
go.drugbank.com/drugs/DB11207ApprovedAmiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].
Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalCurrent strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. … By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedComposed of two hydrophilic side-chains attached to a hydrophobic center core [A27218], its average molecular weight is 8400 Daltons. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalNatalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFlibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … In December of 2025 the FDA expanded the age of the indication to include postmenopausal women, a first for the FDA and sexual health in that age group. [L54893]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGliclazide
go.drugbank.com/drugs/DB01120ApprovedInvestigationala sulfonamide group able to release a proton and the presence of one aromatic group. … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.
Products: GLICLAZIDE GENTIAN GENERICS, GLICLAZIDE DOC GENERICISomatrem
go.drugbank.com/drugs/DB09098ApprovedWithdrawnDespite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents … continues to be mired in persistent bioethical debate [A32292].
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalIt promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Mixtures: Dilantin W Phenobarbital 15mg, Dilantin W Phenobarbital 30mg Cap